SCHEMBL21600784

SCHEMBL21600784

CC(C)(C)OC(=O)Nc1cc(N2CCC(N3CCCC3)CC2)ccc1N

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 2/20 0.44
PTK6 Q13882 2/20 0.44
L3MBTL3 Q96JM7 5/20 0.44
L3MBTL1 Q9Y468 4/20 0.44
SRC P12931 1/20 0.43
HDAC1 Q13547 4/20 0.43
MBTD1 Q05BQ5 2/20 0.43
TP53BP1 Q12888 1/20 0.43
L3MBTL4 Q8NA19 1/20 0.43
HDAC4 P56524 1/20 0.42
NPY2R P49146 3/20 0.41
OPRM1 P35372 1/20 0.41
OPRD1 P41143 1/20 0.41
OGFRL1 Q5TC84 1/20 0.41
HDAC2 Q92769 3/20 0.41
HDAC3 O15379 2/20 0.41
LGMN Q99538 1/20 0.40
GPR119 Q8TDV5 1/20 0.40
LRRK2 Q5S007 1/20 0.39
FGFR1 P11362 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21600861 0.99 ABL1 (0.45) ABL1PTK6L3MBTL3L3MBTL1SRC
SCHEMBL30044386 0.99 ABL1 (0.45) ABL1PTK6L3MBTL3L3MBTL1SRC
SCHEMBL25139823 0.98 ABL1 (0.42) ABL1PTK6L3MBTL3L3MBTL1SRC
SCHEMBL30044118 0.98 ABL1 (0.42) ABL1PTK6L3MBTL3L3MBTL1SRC
SCHEMBL30044058 0.92 OPRM1 (0.40) ABL1PTK6SRCHDAC1OPRM1
SCHEMBL23606381 0.92 OPRM1 (0.40) ABL1PTK6SRCHDAC1OPRM1
SCHEMBL21600862 0.92 HDAC2 (0.42) ABL1PTK6SRCHDAC1HDAC2
SCHEMBL30044362 0.92 LGMN (0.41) ABL1PTK6SRCHDAC1OPRM1
SCHEMBL23606385 0.92 LGMN (0.41) ABL1PTK6SRCHDAC1OPRM1
SCHEMBL25139909 0.91 HDAC1 (0.39) ABL1PTK6SRCHDAC1OPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12582654-B2 Cyano-substituted pyridine and cyano-substituted pyrimidine compound and preparation method therefor and application thereof BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) 2026-03-24 US disclosed
EP-4083021-B1 CYANO-SUBSTITUTED PYRIDINE AND CYANO-SUBSTITUTED PYRIMIDINE COMPOUND AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF BEIJING SCITECH MQ PHARMACEUTICALS LTD (CN) 2025-07-02 EP disclosed
US-20230125046-A1 CYANO-SUBSTITUTED PYRIDINE AND CYANO-SUBSTITUTED PYRIMIDINE COMPOUND AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) 2023-04-20 US disclosed
US-20230125046-A1 CYANO-SUBSTITUTED PYRIDINE AND CYANO-SUBSTITUTED PYRIMIDINE COMPOUND AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) 2023-04-20 US disclosed
EP-4083021-A1 CYANO-SUBSTITUTED PYRIDINE AND CYANO-SUBSTITUTED PYRIMIDINE COMPOUND AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF Beijing Scitech-MQ Pharmaceuticals Limited (CN) 2022-11-02 EP disclosed
WO-2019242689-A1 CYANO-SUBSTITUTED PYRIDINE AND CYANO-SUBSTITUTED PYRIMIDINE COMPOUND, AND PREPARATION METHOD AND APPLICATION THEREOF 北京赛特明强医药科技有限公司 2019-12-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230125046-A1 CYANO-SUBSTITUTED PYRIDINE AND CYANO-SUBSTITUTED PYRIMIDINE COMPOUND AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF FGFR4, FGFR1, WEE1 ABL1 554/4885PTK6 438/4885L3MBTL3 3783/4885
US-12582654-B2 Cyano-substituted pyridine and cyano-substituted pyrimidine compound and preparation method therefor and application thereof FGFR4, FGFR3, FGFR1 ABL1 131/4885PTK6 605/4885L3MBTL3 2204/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.